Source: Haematologica. Unidade: FM
Subjects: LINFOMA, PROGNÓSTICO, SOBREVIVÊNCIA LIVRE DE DOENÇA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VERHOEF, Gregor et al. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study. Haematologica, v. 102, n. 5, p. 895-902, 2017Tradução . . Disponível em: https://doi.org/10.3324/haematol.2016.152496. Acesso em: 04 out. 2024.APA
Verhoef, G., Robak, T., Huang, H., Pylypenko, H., Siritanaratkul, N., Pereira, J., et al. (2017). Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study. Haematologica, 102( 5), 895-902. doi:10.3324/haematol.2016.152496NLM
Verhoef G, Robak T, Huang H, Pylypenko H, Siritanaratkul N, Pereira J, Drach J, Mayer J, Okamoto R, Pei L, Rooney B, Cakana A, Velde H van de, Cavalli F. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study [Internet]. Haematologica. 2017 ; 102( 5): 895-902.[citado 2024 out. 04 ] Available from: https://doi.org/10.3324/haematol.2016.152496Vancouver
Verhoef G, Robak T, Huang H, Pylypenko H, Siritanaratkul N, Pereira J, Drach J, Mayer J, Okamoto R, Pei L, Rooney B, Cakana A, Velde H van de, Cavalli F. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study [Internet]. Haematologica. 2017 ; 102( 5): 895-902.[citado 2024 out. 04 ] Available from: https://doi.org/10.3324/haematol.2016.152496
